Roche and Discuva partner to combat drug-resistant infections

03/1/2014 | Genetic Engineering & Biotechnology News

Roche Holding and Discuva have entered a licensing partnership to discover and develop antibiotics to treat infections caused by multidrug-resistant Gram-negative bacteria using Discuva's SATIN technology platform. Under the agreement, Discuva will receive $16 million upfront and up to $175 million for every product developed as well as royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX